HTG Molecular Diagnostics, Inc. reaffirmed revenue guidance for the year ended December 31, 2019. Pursuant to this Current Report on Form 8-K, the company announcing that, for the year ended December 31, 2019, The company expects to report direct revenue of approximately $14.6 million. Direct revenue consists of product and product-related services revenue, which includes biomarker profiling revenue generated through the sale of the company's HTG EdgeSeq instruments and consumables and from services performed for customers in the company's VERI/O laboratory using the company's proprietary research use only technology. As previously announced on January 13, 2020, The company expects to report total revenue for the year ended December 31, 2019 of approximately $19.2 million.